We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+34.37%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$893M
AUM Growth
+$128M
Cap. Flow
-$69.5M
Cap. Flow %
-7.78%
Top 10 Hldgs %
49.95%
Holding
59
New
4
Increased
15
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
ACIU icon
AC Immune
ACIU
+$33.2M
2
CTMX icon
CytomX Therapeutics
CTMX
+$17.7M
3
MRSN
Mersana Therapeutics
MRSN
+$12.6M
4
REPL icon
Replimune Group
REPL
+$8.82M
5
OVID icon
Ovid Therapeutics
OVID
+$8.24M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$59.7M
2
ARRY
Array Biopharma Inc
ARRY
+$27.6M
3
XNCR icon
Xencor
XNCR
+$19.7M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$17.5M
5
PVLA
Palvella Therapeutics
PVLA
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 90.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLRX
26
BioLineRX
BLRX
$12.2M
$11.2M 1.25%
43,326
– –
SNDX icon
27
Syndax Pharmaceuticals
SNDX
$1.67B
$10.4M 1.17%
1,987,669
– –
VSTM icon
28
Verastem
VSTM
$490M
$10.4M 1.16%
292,833
– –
ARGX icon
29
argenx
ARGX
$53.7B
$10.1M 1.13%
80,868
– –
FWP
30
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$10M 1.12%
1,211,440
– –
FSTX
31
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$9.98M 1.12%
237,925
– –
EIGR
32
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$9.44M 1.06%
22,500
– –
VBIV
33
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$8.83M 0.99%
157,419
-16,476
-9% -$891K
CRVS icon
34
Corvus Pharmaceuticals
CRVS
$1.12B
$8.48M 0.95%
2,109,342
+218,835
+12% +$924K
LITS
35
Lite Strategy Inc
LITS
$33.3M
$8.29M 0.93%
134,938
-13,997
-9% -$802K
ALPN
36
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.24M 0.92%
1,201,717
+558,658
+87% +$3.48M
CTIC
37
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$6.72M 0.75%
6,929,690
– –
ALBO
38
DELISTED
Albireo Pharma Inc
ALBO
$6.46M 0.72%
200,500
– –
VYGR icon
39
Voyager Therapeutics
VYGR
$184M
$5.94M 0.67%
+310,299
New +$4.04M
SPRO icon
40
Spero Therapeutics
SPRO
$68.3M
$5.9M 0.66%
460,706
-382,440
-45% -$4.06M
OVID icon
41
Ovid Therapeutics
OVID
$420M
$5.83M 0.65%
+3,293,000
New +$8.24M
PHXM
42
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$4.75M 0.53%
62,500
– –
GNCA
43
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.62M 0.52%
978,530
+339,223
+53% +$1.68M
CDTX
44
DELISTED
Cidara Therapeutics
CDTX
$4.53M 0.51%
85,534
-59,700
-41% -$3.27M
OMED
45
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$4.27M 0.48%
4,108,815
+65,826
+2% +$53.6K
VIRX
46
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.78M 0.31%
65,367
– –
FRTX
47
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$2.73M 0.31%
7,235
+3,153
+77% +$1.06M
RLM
48
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
$2.41M 0.27%
612,889
+252,023
+70% +$707K
SURF
49
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2.15M 0.24%
451,850
– –
EPIX
50
DELISTED
ESSA Pharma
EPIX
$1.99M 0.22%
580,368
– –
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2019 Portfolio in Review

As of Q1 2019, BVF Inc held 59 positions worth $893M, up 17% from $765M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

BVF Inc withdrew a net $69.5M in Q1 2019, closing 6 positions and reducing 14 holdings. Its most notable exit was Immune Design Corp., an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 83% a quarter earlier.

Against the trend, BVF Inc opened a new position in CytomX Therapeutics worth $12.9M.

  • BVF Inc's largest Q1 2019 buy was CytomX Therapeutics: 1,198,000 shares worth $12.9M.
  • BVF Inc added most to AC Immune in Q1 2019, an estimated $33.2M increase.
  • BVF Inc's biggest Q1 2019 reduction was ChemoCentryx, Inc., cutting an estimated $59.7M.
  • BVF Inc fully exited Immune Design Corp. in Q1 2019, selling an estimated $6.74M.
  • BVF Inc's ten largest holdings make up 50% of its $893M portfolio in Q1 2019.
  • BVF Inc opened 4 new positions and closed 6 in Q1 2019.
  • BVF Inc's portfolio value rose 17% quarter-over-quarter to $893M.

Based on BVF Inc's 13F filing for Q1 2019, filed 15 May 2019.